Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896159 | 0.86 | ICAM1 (0.42) | ESR1ESR2ICAM1SELEHTT | |
| SCHEMBL12896185 | 0.80 | BCL2L1 (0.39) | — | |
| SCHEMBL12896176 | 0.79 | BCKDK (0.38) | MEN1KMT2A | |
| SCHEMBL12896165 | 0.78 | HSD17B10 (0.37) | — | |
| SCHEMBL12896179 | 0.73 | GPR3 (0.46) | MEN1KMT2A | |
| SCHEMBL12248513 | 0.71 | ICAM1 (0.42) | ESR1ESR2ICAM1SELEHTT | |
| SCHEMBL17232354 | 0.71 | UGT2B7 (0.35) | TDP1 | |
| SCHEMBL3874783 | 0.71 | HTT (0.44) | ESR1ESR2HTT | |
| SCHEMBL29980342 | 0.71 | HTT (0.44) | ESR1ESR2HTT | |
| SCHEMBL20708908 | 0.70 | ESR1 (0.38) | ESR1ESR2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | ESR1 296/4885ESR2 220/4885ICAM1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.